Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Correlations between the expression of metabolism-related proteins and clinicopathologic parameters a

From: Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype

Parameters Glut-1 in tumor Glut-1 in stroma CAIX in tumor CAIX in stroma    
Negative Positive   Negative Positive   Negative Positive   Negative Positive     
  (n= 504) (%) (n= 236) (%) P-value (n= 724) (%) (n= 16) (%) P-value (n= 520) (%) (n= 220) (%) P-value (n= 627) (%) (n= 113) (%) P-value    
Age (years, mean ± SD) 50.5 ± 10.7 48.1 ± 11.4 0.126 49.7 ± 110.0 49.3 ± 9.0 18.14 49.7 ± 11.0 49.8 ± 11.0 19.67 49.3 ± 11.1 51.7 ± 10.3 0.840    
Histologic grade    <0.001    8.946    0.441    0.483    
 I/II 392 (71.8) 99 (41.9)   482 (67.3) 9 (56.3)   359 (69.0) 132 (60.0)   427 (68.1) 64 (56.6)     
 III 112 (22.2) 137 (58.1)   242 (33.4) 7 (43.7)   161 (31.0) 88 (40.0)   200 (31.9) 49 (43.4)     
ER    <0.001    0.378    0.042    1.113    
 Negative 128 (25.4) 158 (66.9)   275 (38.0) 11 (68.8)   182 (35.0) 104 (47.3)   233 (37.2) 53 (46.9)     
 Positive 376 (74.6) 78 (33.1)   449 (62.0) 5 (31.2)   338 (65.0) 116 (52.7)   394 (62.8) 60 (53.1)     
PR    <0.001    4.305    10.92    8.715    
 Negative 190 (37.7) 182 (77.1)   361 (49.9) 11 (68.8)   257 (49.4) 115 (52.3)   311 (49.6) 61 (54.0)     
 Positive 314 (62.3) 54 (22.9)   363 (50.1) 5 (31.2)   263 (50.6) 105 (47.7)   316 (50.4) 52 (46.0)     
HER2    0.714    6.741    0.294    1.260    
 Negative 386 (76.6) 197 (83.5)   572 (79.0) 11 (68.8)   397 (76.3) 186 (84.5)   502 (80.1) 81 (71.7)     
 Positive 118 (23.4) 39 (16.5)   152 (21.0) 5 (31.2)   123 (23.7) 34 (15.5)   125 (19.9) 32 (28.3)     
Tumor stage    <0.001    18.81    19.65    3.192    
 T1 270 (53.6) 88 (37.3)   350 (48.3) 8 (50.0)   251 (48.3) 107 (48.6)   296 (47.2) 62 (54.9)     
 T2/T3 234 (46.4) 148 (62.7)   374 (51.7) 8 (50.0)   269 (51.7) 113 (51.4)   331 (52.8) 51 (45.1)     
Nodal stage    1.932    16.12    15.62    15.87    
 N0 286 (56.7) 150 (63.6)   426 (58.8) 10 (62.5)   304 (58.5) 132 (60.0)   371 (59.2) 65 (57.5)     
 N1/N2/N3 218 (43.3) 86 (36.4)   298 (41.2) 6 (37.5)   216 (41.5) 88 (40.0)   256 (40.8) 48 (42.5)     
Ki-67 LI (%, mean ± SD) 12.7 ± 14.9 29.6 ± 22.1 <0.001 18.0 ± 19.3 22.5 ± 14.7 7.497 16.1 ± 17.5 22.7 ± 22.1 <0.001 17.8 ± 19.7 19.5 ± 16.7 8.505    
Tumor recurrence    0.210    8.106    18.62    17.85    
 Absent 467 (92.7) 204 (86.4)   655 (90.5) 16 (100.0)   471 (90.6) 200 (90.9)   568 (90.6) 103 (91.2)     
 Present 37 (7.3) 32 (13.6)   69 (9.5) 0 (0.0)   49 (9.4) 20 (9.1)   59 (9.4) 10 (9.8)     
Death    0.420    8.085    11.76    15.22    
 Survival 467 (92.7) 206 (87.3)   657 (90.7) 16 (100.0)   475 (91.3) 198 (90.0)   571 (91.1) 102 (90.3)     
 Death 37 (7.3) 30 (12.7)   67 (9.3) 0 (0.0)   45 (8.7) 22 (10.0)   56 (8.9) 11 (9.7)     
Parameters ATP synthase in tumor ATP synthase in stroma Glutaminase in tumor Glutaminase in stroma    
  Negative Positive   Negative Positive   Negative Positive   Negative Positive     
  ( n = 30) (%) ( n = 710) (%) P -value ( n = 570) (%) ( n = 170) (%) P -value ( n = 219) (%) ( n = 521) (%) P -value ( n = 495) (%) ( n = 245) (%) P -value    
Age (years, mean ± SD) 46.7 ± 9.3 49.9 ± 11.0 2.478 49.5 ± 11.2 50.4 ± 10.0 7.539 49.2 ± 11.6 49.9 ± 10.7 11.90 49.5 ± 11.1 50.4 ± 10.7 5.124    
Histologic grade    11.63    0.252    16.77    0.168    
 I/II 22 (733) 469 (66.1)   392 (68.8) 99 (58.2)   147 (67.1) 344 (66.0)   345 (69.7) 146 (59.6)     
 III 8 (26.7) 241 (33.9)   178 (31.2) 71 (41.8)   72 (32.9) 177 (34.0)   150 (30.3) 99 (40.4)     
ER    1.827    1.533    4.536    0.126    
 Negative 7 (23.3) 279 (39.3)   210 (36.8) 76 (44.7)   77 (35.2) 209 (40.1)   174 (35.2) 112 (45.7)     
 Positive 23 (76.7) 431 (60.7)   360 (63.2) 94 (55.3)   142 (64.8) 312 (59.9)   321 (64.8) 133 (54.3)     
PR    0.189    0.609    4.158    0.735    
 Negative 8 (26.7) 364 (51.3)   274 (48.1) 98 (57.6)   102 (46.6) 270 (51.8)   235 (47.5) 137 (55.9)     
 Positive 22 (73.3) 346 (48.7)   296 (51.9) 72 (42.4)   117 (53.4) 251 (48.2)   260 (52.5) 108 (44.1)     
HER2    3.570    <0.001    13.08    3.822    
 Negative 27 (90.0) 556 (78.3)   472 (82.8) 111 (65.3)   170 (77.6) 413 (79.3)   397 (80.2) 186 (75.9)     
 Positive 3 (10.0) 154 (21.7)   98 (17.2) 59 (34.7)   49 (22.4) 108 (20.7)   98 (19.8) 59 (24.1)     
Tumor stage    7.539    21.00    7.875    18.39    
 T1 12 (40.0) 346 (48.7)   276 (48.4) 82 (48.2)   100 (45.7) 258 (49.5)   238 (48.1) 120 (49.0)     
 T2/T3 18 (60.0) 364 (51.3)   294 (51.6) 88 (51.8)   119 (54.3) 263 (50.5)   257 (51.9) 125 (51.0)     
Nodal stage    7.266    6.027    7.728    8.967    
 N0 15 (50.0) 421 (59.3)   342 (60.0) 94 (55.3)   135 (61.6) 301 (57.8)   297 (60.0) 139 (56.7)     
 N1/N2/N3 15 (50.0) 289 (40.7)   228 (40.0) 76 (44.7)   84 (38.4) 220 (42.2)   198 (40.0) 106 (43.3)     
Ki-67 LI (%, mean ± SD) 9.8 ± 11.7 18.4 ± 19.4 0.336 17.3 ± 19.7 20.8 ± 17.5 0.798 18.6 ± 20.0 17.8 ± 18.9 13.50 15.6 ± 17.2 22.9 ± 22.0 0.021    
Tumor recurrence    10.79    21.00    7.014    10.56    
 Absent 26 (86.7) 645 (90.8)   517 (90.7) 154 (90.6)   195 (89.0) 476 (91.4)   446 (90.1) 225 (91.8)     
 Present 4 (13.3) 65 (9.2)   53 (9.3) 16 (9.4)   24 (11.0) 45 (8.6)   49 (9.9) 20 (8.2)     
Death    15.68    13.60    3.381    8.757    
 Survival 27 (90.0) 646 (91.0)   520 (91.2) 153 (90.0)   194 (88.6) 479 (91.9)   447 (90.3) 226 (92.2)     
 Death 3 (10.0) 64 (9.0)   50 (8.8) 17 (10.0)   25 (11.4) 42 (8.1)   48 (9.7) 19 (7.8)     
Parameters BNIP3 in tumor BNIP3 in stroma MCT4 in tumor MCT4 in stroma    
Negative Positive   Negative Positive   Negative Positive   Negative Positive     
  ( n =504) (%) ( n = 236) (%) P -value ( n = 700) (%) ( n = 40) (%) P -value ( n = 540) (%) ( n = 200) (%) P -value ( n = 418) (%) ( n = 322) (%) P -value    
Age (years, mean ± SD) 48.9 ± 10.9 51.6 ± 11.0 0.042 49.5 ± 10.8 53.2 ± 12.7 0.882 49.8 ± 11.1 49.6 ± 10.6 17.91 49.6 ± 11.0 49.5 ± 10.9 14.80    
Histologic grade    5.859    15.37    <0.001    <0.001    
 I/II 341 (67.7) 150 (63.6)   463 (66.1) 28 (70.0)   386 (71.5) 105 (52.5)   314 (75.1) 177 (55.0)     
 III 163 (32.3) 86 (36.4)   237 (33.9) 12 (30.0)   154 (28.5) 95 (47.5)   104 (24.9) 145 (45.0)     
ER    14.40    12.99    <0.001    <0.001    
 Negative 192 (38.1) 94 (39.8)   269 (38.4) 17 (42.5)   174 (32.2) 112 (56.0)   123 (29.4) 163 (50.6)     
 Positive 312 (61.9) 142 (60.2)   431 (61.6) 23 (57.5)   366 (67.8) 88 (44.0)   295 (70.6) 159 (49.4)     
PR    17.07    8.757    <0.001    <0.001    
 Negative 255 (50.6) 117 (49.6)   349 (49.9) 23 (57.5)   232 (43.0) 140 (70.0)   179 (42.8) 193 (60.0)     
 Positive 249 (49.4) 119 (50.4)   351 (50.1) 17 (42.5)   308 (57.0) 60 (30.0)   239 (57.2) 129 (40.0)     
HER2    4.410    6.762    11.42    <0.001    
 Negative 404 (80.2) 179 (75.8)   554 (79.1) 29 (72.5)   422 (78.1) 161 (80.5)   356 (85.2) 227 (70.5)     
 Positive 100 (19.8) 57 (24.2)   146 (20.9) 11 (27.5)   118 (21.9) 39 (19.5)   62 (14.8) 95 (29.5)     
Tumor stage    1.449    15.66    <0.001    7.854    
 T1 232 (46.0) 126 (53.4)   340 (48.6) 18 (45.0)   283 (52.4) 75 (37.5)   196 (46.9) 162 (50.3)     
 T2/T3 272 (54.0) 110 (46.6)   360 (51.4) 22 (55.0)   257 (47.6) 125 (62.5)   222 (53.1) 160 (49.7)     
Nodal stage    6.237    0.630    18.20    7.686    
 N0 290 (57.5) 146 (61.9)   419 (59.9) 17 (42.5)   317 (58.7) 119 (59.5)   240 (57.4) 196 (60.9)     
 N1/N2/N3 214 (42.5) 90 (38.1)   281 (40.1) 23 (57.5)   223 (41.3) 81 (40.5)   178 (42.6) 126 (39.1)     
Ki-67 LI (%, mean ± SD) 18.9 ± 20.9 16.2 ± 15.0 1.680 18.3 ± 19.5 14.6 ± 13.7 5.208 15.3 ± 17.8 25.6 ± 21.0 <0.001 13.2 ± 16.5 24.3 ± 20.7 <0.001    
Tumor recurrence    0.021    3.444    14.11    11.00    
 Absent 445 (88.3) 226 (95.8)   632 (90.3) 39 (97.5)   491 (90.9) 180 (90.0)   376 (90.0) 295 (91.6)     
 Present 59 (11.7) 10 (4.2)   68 (9.7) 1 (2.5)   49 (9.1) 20 (10.0)   42 (10.0) 27 (8.4)     
Death    5.712    15.22    11.90    2.562    
 Survival 454 (90.1) 219 (92.8)   636 (90.9) 37 (92.5)   493 (91.3) 180 (90.0)   374 (89.5) 299 (92.9)     
 Death 50 (9.9) 17 (7.2)   64 (9.1) 3 (7.5)   47 (8.7) 20 (10.0)   44 (10.5) 23 (7.1)     
Parameters Cytoplasmic Beclin-1 Nuclear Beclin-1 LC3A in tumor LC3A in stroma    
Negative Positive   Negative Positive   Negative Positive   Negative Positive     
  ( n = 406) (%) ( n = 334) (%) P -value ( n = 666) (%) ( n = 74) (%) P -value ( n = 669) (%) ( n = 71) (%) P -value ( n = 687) (%) ( n = 53) (%) P -value    
Age (years, mean ± SD) 48.6 ± 10.5 51.1 ± 11.4 0.042 49.6 ± 11.1 50.8 ± 9.9 8.316 50.2 ± 11.0 45.6 ± 9.8 0.021 49.7 ± 11.0 49.6 ± 9.2 19.65    
Histologic grade    14.61    <0.001    <0.001    1.029    
 I/II 272 (67.0) 219 (65.6)   427 (64.1) 64 (86.5)   470 (70.3) 21 (29.6)   449 (65.4) 42 (79.2)     
 III 134 (33.0) 115 (34.4)   239 (35.9) 10 (13.5)   199 (29.7) 50 (70.4)   238 (34.6) 11 (20.8)     
ER    6.090    8.022    <0.001    <0.001    
 Negative 143 (35.2) 143 (42.8)   261 (39.2) 25 (33.8)   226 (33.8) 60 (84.5)   278 (40.5) 8 (15.1)     
 Positive 263 (64.8) 191 (57.2)   405 (60.8) 49 (66.2)   443 (66.2) 11 (15.5)   409 (59.5) 45 (84.9)     
PR    19.76    1.827    <0.001    <0.001    
 Negative 205 (50.5) 167 (50.0)   342 (51.4) 30 (40.5)   309 (46.2) 63 (88.7)   360 (52.4) 12 (22.6)     
 Positive 201 (49.5) 167 (50.0)   324 (48.6) 44 (59.5)   360 (53.8) 8 (11.3)   327 (47.6) 41 (77.4)     
HER2    12.36    0.336    <0.001    8.022    
 Negative 323 (79.6) 260 (77.8)   533 (80.0) 50 (67.6)   515 (76.9) 68 (95.8)   544 (79.2) 39 (73.6)     
 Positive 83 (20.4) 74 (22.2)   133 (20.0) 24 (32.4)   154 (23.1) 3 (4.2)   143 (20.8) 14 (26.4)     
Tumor stage    0.042    6.888    16.86    0.210    
 T1 175 (43.1) 183 (54.8)   318 (47.7) 40 (54.1)   325 (48.6) 33 (46.5)   323 (47.0) 35 (66.0)     
 T2/T3 231 (56.9) 151 (45.2)   348 (52.3) 34 (45.9)   344 (51.4) 38 (53.5)   364 (53.0) 18 (34.0)     
Nodal stage    13.71    3.612    6.552    16.23    
 N0 236 (58.1) 200 (59.9)   398 (59.8) 38 (51.4)   390 (58.3) 46 (64.8)   406 (59.1) 30 (56.6)     
 N1/N2/N3 170 (41.9) 134 (40.1)   268 (40.2) 36 (48.6)   279 (41.7) 25 (35.2)   281 (40.9) 23 (43.4)     
Ki-67 LI (%, mean ± SD) 17.8 ± 19.4 18.3 ± 19.1 0.042 19.0 ± 19.8 9.5 ± 10.0 <0.001 15.7 ± 17.2 39.6 ± 23.1 <0.001 18.7 ± 19.7 10.4 ± 9.6 0.032    
Tumor recurrence    0.882    2.877    4.053    16.98    
 Absent 360 (88.7) 311 (93.1)   600 (90.1) 71 (95.9)   610 (91.2) 61 (85.9)   622 (90.5) 49 (92.5)     
 Present 46 (11.3) 23 (6.9)   66 (9.9) 3 (4.1)   59 (8.8) 10 (14.1)   65 (9.5) 4 (7.5)     
Death    16.75    0.189    10.75    9.765    
 Survival 368 (90.6) 305 (91.3)   600 (90.1) 73 (98.6)   610 (91.2) 63 (88.7)   623 (90.7) 50 (94.3)     
 Death 38 (9.4) 29 (8.7)   66 (9.9) 1 (1.4)   59 (8.8) 8 (11.3)   64 (9.3) 3 (5.7)     
Parameters LC3B in tumor LC3B in stroma Cytoplasmic p62 in tumor Nuclear p62 in tumor Nuclear p62 in stroma
Negative Positive   Negative Positive   Negative Positive   Negative Positive   Negative Positive  
  ( n = 475) (%) (n = 265) (%) P -value ( n = 688) (%) ( n = 52) (%) P -value ( n = 274) (%) ( n = 466) (%) P -value ( n = 532) (%) ( n = 208) (%) P -value ( n = 512) (%) ( n = 228) (%) P -value
Age 49.4 ± 10.4 50.4 ± 12.0 4.599 49.6 ± 11.0 51.1 ± 10.6 15.77 49.4 ± 10.3 49.9 ± 11.4 10.35 49.4 ± 10.9 50.6 ± 11.2 3.717 49.5 ± 11.2 50.3 ± 10.4 6.741
(years, mean ± SD)
Histologic grade    3.528    9.450    0.210    <0.001    18.18
 I/II 324 (68.2) 167 (63.0)   459 (66.7) 32 (61.5)   198 (72.3) 293 (62.9)   322 (60.5) 169 (81.3)   341 (66.6) 150 (65.8)  
 III 151 (31.8) 98 (37.0)   229 (33.3) 20 (38.5)   76 (27.7) 173 (37.1)   210 (39.5) 39 (18.8)   171 (33.4) 78 (34.2)  
ER    6.279    7.980    2.877    <0.001    14.34
 Negative 173 (36.4) 113 (42.6)   269 (39.1) 17 (32.7)   96 (35.0) 190 (40.8)   227 (42.7) 59 (28.4)   195 (38.1) 91 (39.9)  
 Positive 302 (63.6) 152 (57.4)   419 (60.9) 35 (67.3)   178 (65.0) 276 (59.2)   305 (57.3) 149 (71.6)   317 (61.9) 137 (60.1)  
PR    10.29    5.292    0.105    <0.001    17.05
 Negative 234 (49.3) 138 (52.1)   350 (50.9) 22 (42.3)   119 (43.4) 253 (54.3)   293 (55.1) 79 (38.0)   259 (50.6) 113 (49.6)  
 Positive 241 (50.7) 127 (47.9)   338 (49.1) 30 (57.7)   155 (56.6) 213 (45.7)   239 (44.9) 129 (62.0)   253 (49.4) 115 (50.4)  
HER2    12.07    12.55    <0.001    16.04    13.16
 Negative 371 (78.1) 212 (80.0)   540 (78.5) 43 (82.7)   238 (86.9) 345 (74.0)   421 (79.1) 162 (77.9)   406 (79.3) 177 (34.6)  
 Positive 104 (21.9) 53 (20.0)   148 (21.5) 9 (17.3)   36 (13.1) 121 (26.0)   111 (20.9) 46 (22.1)   106 (20.7) 51 (22.4)  
Tumor stage    0.357    14.00    3.570    0.189    0.189
 T1 214 (45.1) 144 (54.3)   331 (48.1) 27 (51.9)   142 (51.8) 216 (46.4)   241 (45.3) 117 (56.2)   231 (45.1) 127 (55.7)  
 T2/T3 261 (54.9) 121 (45.7)   357 (51.9) 25 (48.1)   132 (48.2) 250 (53.6)   291 (54.7) 91 (43.8)   281 (54.9) 101 (44.3)  
Nodal stage    6.531    13.90    3.969    5.901    10.87
 N0 273 (57.5) 163 (61.5)   407 (59.2) 29 (55.8)   170 (62.0) 266 (57.1)   320 (60.2) 116 (55.8)   306 (59.8) 130 (57.0)  
 N1/N2/N3 202 (42.5) 102 (38.5)   281 (40.8) 23 (44.2)   104 (38.0) 200 (42.9)   212 (39.8) 92 (44.2)   206 (40.2) 98 (43.0)  
Ki-67 LI (%, mean ± SD) 18.2 ± 19.8 17.8 ± 18.2 16.10 18.4 ± 19.4 18.9 ± 17.6 15.77 16.0 ± 19.2 19.3 ± 19.2 0567 21.4 ± 20.8 9.5 ± 10.6 <0.001 18.5 ± 19.7 17.0 ± 18.1 7.161
Tumor recurrence    18.81    9.765    18.83    3.339    19.80
 Absent 430 (90.5) 241 (90.9)   622 (90.4) 49 (94.2)   248 (90.5) 423 (90.8)   477 (89.7) 194 (93.3)   464 (90.6) 207 (90.8)  
 Present 45 (9.5) 24 (9.1)   66 (9.6) 3 (5.8)   26 (9.5) 43 (9.2)   55 (10.3) 14 (6.7)   48 (9.4) 21 (9.2)  
Death    8.925    12.89    14.53    10.03    14.28
 Survival 435 (91.6) 238 (89.8)   624 (90.7) 49 (94.2)   251 (91.6) 422 (90.6)   481 (90.4) 192 (92.3)   467 (91.2) 206 (90.3)  
 Death 40 (8.4) 27 (10.2)   64 (9.3) 3 (5.8)   23 (8.4) 44 (9.4)   51 (9.6) 16 (7.7)   45 (8.8) 22 (9.7)  
  1. aP-values are corrected for multiple testing using the Bonferroni correction. BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; LI, labeling index; MCT4, monocarboxylate transporter 4; TNBC, triple-negative breast cancer.